Previous close | 87.74 |
Open | 88.18 |
Bid | 88.60 x 400 |
Ask | 88.71 x 400 |
Day's range | 87.94 - 88.74 |
52-week range | 76.02 - 100.38 |
Volume | |
Avg. volume | 1,325,206 |
Market cap | 16.719B |
Beta (5Y monthly) | 0.31 |
PE ratio (TTM) | 101.85 |
EPS (TTM) | 0.87 |
Earnings date | 24 Apr 2024 - 29 Apr 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 109.48 |
BioMarin Pharmaceutical Inc. (Nasdaq: BMRN) announced that positive early results from an investigator-sponsored Phase 2 study of VOXZOGO® (vosoritide) in children with hypochondroplasia, will be presented at the 2024 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting in Toronto, Canada, March 12-16, 2024. Researchers will also present data from Phase 2 and Phase 3 studies of the medicine in children with achondroplasia, including results that demonstrate V
The company is a leader in the global achondroplasia treatment market
Henry Fuchs, President, Worldwide Research & Development at Biomarin Pharmaceutical Inc (NASDAQ:BMRN), sold 35,341 shares of the company on March 5, 2024, according to a recent SEC filing.